Here's why 'Jekyll and Hyde' protein prevents as well as spreads cancer

Image
ANI Washington
Last Updated : Feb 10 2015 | 5:00 PM IST

A new research has explained why a protein that suppresses tumors also causes metastasis.

Scottish author Robert Louis Stevenson tapped into primal fears when he penned "Dr. Jekyll and Mr. Hyde," a 19th century novel about a sinister physician, raising the question, "Can evil and good exist in the same person?"

As it turns out, cancer researchers are discovering that "good vs. bad" can also exist in the world of molecular genetics and one example is a protein, transforming growth factor beta (TGF-Beta) that suppresses tumor progression in pre-malignant cells, can also lead to the spread of cancer.

It has been a long-time puzzle how and when TGF-Beta switches its functional roles from a tumor suppressor to a metastasis promoter and now, scientists at The University of Texas believe they have an answer.

The research demonstrates that another protein, known as 14-3-3 zeta, can switch TGF-Beta from suppressing tumors in pre-cancerous cells to promoting metastasis in breast cancer cells, spreading to the bones by changing the TGF-Beta's partner proteins.

Dihua Yu said that TGF-Beta has a dual role as both a tumor suppressor in normal and pre-malignant cells, and a metastasis promoter in late-stage cancer and the molecular mechanism by which TGF-Beta switches its role has long been an unsolved mystery for cancer researchers.

Yu added that TGF-Beta's known critical role in cancer has led to numerous efforts developing TGF-Beta inhibitors for anti-cancer therapeutics, but its penchant for both suppressing tumor progression while serving as a springboard for cancer metastasis has been a major obstacle in the development of anti-TGF-Beta therapies and they have developed a model that proposes that TGF-Beta's complicated nature may be governed by the cellular effects of SMAD's partner proteins.

Yu concluded that because TGF-Beta plays important roles in various physiological functions, it is crucial that we look at how to develop more specific drugs that selectively target TGF-Beta in cancer so as to discourage its ability to cause metastasis while maintaining its tumor suppression abilities in pre-cancerous cells.

The results are published in Cancer Cell.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 10 2015 | 4:50 PM IST

Next Story